Symbols / DCTH Stock $11.07 -3.40% Delcath Systems, Inc.

Healthcare • Medical Devices • United States • NCM
DCTH (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Gerard J. Michel MBA, MS
Exch · Country NCM · United States
Market Cap 382.15M
Enterprise Value 293.76M
Income 561.00K
Sales 90.44M
FCF (ttm) 19.65M
Book/sh 3.27
Cash/sh 2.59
Employees 156
Insider 10d —
IPO May 03, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 1,107.00
Forward P/E -28.88
PEG 1.60
P/S 4.23
P/B 3.39
P/C —
EV/EBITDA -222.21
EV/Sales 3.25
Quick Ratio 9.72
Current Ratio 11.24
Debt/Eq 0.81
LT Debt/Eq —
EPS (ttm) 0.01
EPS next Y -0.38
EPS Growth —
Revenue Growth 26.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -0.95%
ROE 0.58%
ROIC —
Gross Margin 85.97%
Oper. Margin -6.55%
Profit Margin 0.62%
Shs Outstand 34.52M
Shs Float 28.60M
Insider Own 8.13%
Instit Own 48.74%
Short Float 11.19%
Short Ratio 12.61
Short Interest 3.55M
52W High 18.23
vs 52W High -39.28%
52W Low 8.12
vs 52W Low 36.33%
Beta 0.54
Impl. Vol. 70.26%
Rel Volume 1.37
Avg Volume 401.46K
Volume 550.64K
Target (mean) $21.29
Tgt Median $20.00
Tgt Low $18.00
Tgt High $29.76
# Analysts 6
Recom Strong_buy
Prev Close $11.46
Price $11.07
Change -3.40%
About

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.29
Mean price target
2. Current target
$11.07
Latest analyst target
3. DCF / Fair value
$10.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.07
Low
$18.00
High
$29.76
Mean
$21.29

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-26 main BTIG Buy → Buy $19
2026-01-09 reit HC Wainwright & Co. Buy → Buy $30
2025-11-05 main Stephens & Co. Overweight → Overweight $18
2025-11-04 reit BTIG Buy → Buy $23
2025-10-21 main Canaccord Genuity Buy → Buy $21
2025-10-20 main HC Wainwright & Co. Buy → Buy $30
2025-08-07 main HC Wainwright & Co. Buy → Buy $31
2025-06-23 reit Stephens & Co. Overweight → Overweight $25
2025-05-23 main HC Wainwright & Co. Buy → Buy $29
2025-03-07 main HC Wainwright & Co. Buy → Buy $24
2025-01-17 main Craig-Hallum Buy → Buy $21
2025-01-14 reit HC Wainwright & Co. Buy → Buy $22
2024-11-11 reit HC Wainwright & Co. Buy → Buy $22
2024-08-06 reit Stephens & Co. Overweight → Overweight $25
2024-08-06 reit HC Wainwright & Co. Buy → Buy $22
2024-06-28 init Craig-Hallum — → Buy $18
2024-05-15 main HC Wainwright & Co. Buy → Buy $22
2024-05-14 init Stephens & Co. — → Overweight $25
2024-03-27 main HC Wainwright & Co. Buy → Buy $20
2023-09-07 main Canaccord Genuity Buy → Buy $21
News
RSS: Latest DCTH news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-06 PENNELL SANDRA Chief Financial Officer — 5,533 $9.04 $50,018
2026-03-02 MICHEL GERARD J Chief Executive Officer — 11,200 $8.96 $100,309
2025-11-21 SYLVESTER JOHN RICHARD Director — 4,386 $8.89 $38,992
2025-11-11 MICHEL GERARD J Chief Executive Officer — 11,500 $8.53 $98,049
2025-06-12 VUKOVIC VOJISLAV Officer — 42,000 $4.78 $200,760
2025-05-05 ROSALIND ADVISORS, INC. Unknown — 400,000 $10.00 $4,000,000
2025-05-05 SALAMON STEVEN A. J. Director — 400,000 $10.00 $4,000,000
2025-05-05 AHARON GILAD S. Director — 400,000 $10.00 $4,000,000
2024-12-24 ROSALIND ADVISORS, INC. Director — 250,000 $10.00 $2,500,000
2024-12-24 SALAMON STEVEN A. J. Director — 250,000 $10.00 $2,500,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
85.23
+129.08%
37.20
+1701.69%
2.06
-24.05%
2.72
Operating Revenue
85.23
+129.08%
37.20
+1701.69%
2.06
-18.96%
2.55
Cost Of Revenue
11.80
+90.64%
6.19
+874.49%
0.64
-7.43%
0.69
Reconciled Cost Of Revenue
11.80
+90.64%
6.19
+874.49%
0.64
-7.43%
0.69
Gross Profit
73.43
+136.75%
31.02
+2069.02%
1.43
-29.66%
2.03
Operating Expense
72.77
+67.58%
43.43
+9.63%
39.61
+10.38%
35.89
Research And Development
29.25
+110.80%
13.87
-20.73%
17.50
-5.82%
18.58
Selling General And Administration
43.53
+47.29%
29.55
+33.66%
22.11
+27.78%
17.30
Total Expenses
84.57
+70.45%
49.62
+23.28%
40.25
+10.05%
36.57
Operating Income
0.66
+105.32%
-12.41
+67.50%
-38.18
-12.79%
-33.85
Total Operating Income As Reported
0.66
+105.32%
-12.41
+67.50%
-38.18
-12.79%
-33.85
EBITDA
1.01
+108.28%
-12.18
+67.76%
-37.78
-12.15%
-33.69
Normalized EBITDA
1.01
-46.61%
1.89
+106.35%
-29.79
+11.59%
-33.69
Reconciled Depreciation
0.35
+52.40%
0.23
-42.61%
0.40
+202.27%
0.13
EBIT
0.66
+105.32%
-12.41
+67.50%
-38.18
-12.89%
-33.82
Total Unusual Items
—
-14.07
-75.93%
-8.00
—
Total Unusual Items Excluding Goodwill
—
-14.07
-75.93%
-8.00
—
Net Income
2.70
+110.23%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Pretax Income
3.51
+113.30%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Net Non Operating Interest Income Expense
2.92
+2236.00%
0.12
+108.69%
-1.44
+46.41%
-2.69
Interest Expense Non Operating
—
—
1.44
-46.41%
2.69
Net Interest Income
2.92
+2236.00%
0.12
+108.69%
-1.44
+46.41%
-2.69
Interest Expense
—
—
1.44
-46.41%
2.69
Other Income Expense
-0.07
+99.50%
-14.10
-75.02%
-8.06
-26956.67%
0.03
Other Non Operating Income Expenses
-0.07
-133.33%
-0.03
+49.15%
-0.06
-296.67%
0.03
Gain On Sale Of Security
—
-14.07
-75.93%
-8.00
—
Tax Provision
0.81
0.00
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
2.70
+110.23%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Net Income From Continuing Operation Net Minority Interest
2.70
+110.23%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Net Income From Continuing And Discontinued Operation
2.70
+110.23%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Net Income Continuous Operations
2.70
+110.23%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Normalized Income
2.70
+121.92%
-12.31
+68.96%
-39.68
-8.69%
-36.51
Net Income Common Stockholders
2.70
+110.23%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
0.07
+107.53%
-0.93
+68.37%
-2.94
+28.64%
-4.12
Basic EPS
0.08
+108.60%
-0.93
+68.37%
-2.94
+28.64%
-4.12
Basic Average Shares
35.82
+25.64%
28.51
+75.67%
16.23
+0.00%
16.23
Diluted Average Shares
39.92
+40.01%
28.51
+75.67%
16.23
+0.00%
16.23
Diluted NI Availto Com Stockholders
2.70
+110.23%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Total Other Finance Cost
-2.92
-2236.00%
-0.12
-108.69%
1.44
—
Line Item Trend 2023-12-31
Total Assets
38.61
Current Assets
37.16
Cash Cash Equivalents And Short Term Investments
32.45
Cash And Cash Equivalents
12.65
Other Short Term Investments
19.81
Receivables
0.48
Accounts Receivable
0.24
Taxes Receivable
0.09
Accrued Interest Receivable
0.15
Inventory
3.32
Raw Materials
1.44
Work In Process
1.75
Finished Goods
0.13
Prepaid Assets
0.51
Restricted Cash
0.05
Other Current Assets
0.34
Total Non Current Assets
1.46
Net PPE
1.46
Gross PPE
6.53
Accumulated Depreciation
-5.08
Properties
0.00
Buildings And Improvements
1.32
Machinery Furniture Equipment
2.06
Construction In Progress
0.00
Other Properties
1.37
Leases
1.79
Total Liabilities Net Minority Interest
22.84
Current Liabilities
16.45
Payables And Accrued Expenses
4.33
Payables
1.01
Accounts Payable
1.01
Current Accrued Expenses
3.31
Pensionand Other Post Retirement Benefit Plans Current
1.93
Current Debt And Capital Lease Obligation
10.19
Current Debt
10.15
Other Current Borrowings
10.15
Current Capital Lease Obligation
0.04
Current Deferred Liabilities
—
Current Deferred Revenue
—
Total Non Current Liabilities Net Minority Interest
6.39
Long Term Debt And Capital Lease Obligation
0.00
Long Term Debt
—
Long Term Capital Lease Obligation
0.00
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Other Non Current Liabilities
0.84
Stockholders Equity
15.78
Common Stock Equity
15.78
Capital Stock
0.23
Common Stock
0.23
Preferred Stock
0.00
Share Issued
22.76
Ordinary Shares Number
22.76
Treasury Shares Number
0.00
Additional Paid In Capital
520.58
Retained Earnings
-505.16
Gains Losses Not Affecting Retained Earnings
0.14
Other Equity Adjustments
0.14
Total Equity Gross Minority Interest
15.78
Total Capitalization
15.78
Invested Capital
25.93
Total Debt
10.19
Net Debt
—
Capital Lease Obligations
0.04
Net Tangible Assets
15.78
Tangible Book Value
15.78
Derivative Product Liabilities
5.55
Interest Payable
0.71
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
22.52
+220.53%
-18.68
+40.22%
-31.25
-25.25%
-24.95
Cash Flow From Continuing Operating Activities
22.52
+220.53%
-18.68
+40.22%
-31.25
-25.25%
-24.95
Net Income From Continuing Operations
2.70
+110.23%
-26.39
+44.66%
-47.68
-30.60%
-36.51
Depreciation Amortization Depletion
0.35
+52.40%
0.23
-42.61%
0.40
+202.27%
0.13
Depreciation
0.35
+52.40%
0.23
-42.61%
0.40
+202.27%
0.13
Depreciation And Amortization
0.35
+52.40%
0.23
-42.61%
0.40
+202.27%
0.13
Other Non Cash Items
—
0.59
-36.65%
0.94
-31.73%
1.37
Stock Based Compensation
24.23
+148.10%
9.77
+19.83%
8.15
+2.64%
7.94
Operating Gains Losses
—
14.07
+75.93%
8.00
—
Gain Loss On Investment Securities
—
14.07
+75.93%
8.00
—
Change In Working Capital
-3.07
+80.23%
-15.52
-1613.13%
-0.91
-142.86%
2.11
Change In Receivables
-0.85
+91.98%
-10.65
-8619.20%
0.12
+138.82%
-0.32
Changes In Account Receivables
-0.85
+91.98%
-10.65
-8619.20%
0.12
+138.82%
-0.32
Change In Inventory
-3.32
+8.09%
-3.61
-172.73%
-1.32
-125.55%
-0.59
Change In Prepaid Assets
-3.42
-108.72%
-1.64
-259.28%
1.03
+32.95%
0.77
Change In Payables And Accrued Expense
4.77
+894.99%
0.48
+340.70%
-0.20
-111.07%
1.80
Change In Accrued Expense
—
—
—
—
Change In Payable
4.77
+894.99%
0.48
+340.70%
-0.20
—
Change In Account Payable
4.77
+894.99%
0.48
+340.70%
-0.20
—
Change In Other Working Capital
—
—
—
-0.17
Change In Other Current Liabilities
-0.24
-138.61%
-0.10
+81.19%
-0.54
-186.47%
0.62
Investing Cash Flow
-26.59
-2610.50%
-0.98
+95.02%
-19.71
-9330.14%
-0.21
Cash Flow From Continuing Investing Activities
-26.59
-2610.50%
-0.98
+95.02%
-19.71
-9330.14%
-0.21
Net PPE Purchase And Sale
-1.55
-176.74%
-0.56
-863.79%
-0.06
+72.25%
-0.21
Purchase Of PPE
-1.55
-176.74%
-0.56
-863.79%
-0.06
+72.25%
-0.21
Capital Expenditure
-1.55
-176.74%
-0.56
-863.79%
-0.06
+72.25%
-0.21
Net Investment Purchase And Sale
-25.04
-5834.36%
-0.42
+97.85%
-19.65
0.00
Purchase Of Investment
-93.22
-77.71%
-52.45
-166.92%
-19.65
0.00
Sale Of Investment
68.17
+31.02%
52.03
0.00
0.00
Financing Cash Flow
15.05
-61.82%
39.41
-23.89%
51.78
+410.48%
10.14
Cash Flow From Continuing Financing Activities
15.05
-61.82%
39.41
-23.89%
51.78
+410.48%
10.14
Net Issuance Payments Of Debt
0.00
+100.00%
-10.61
-68.07%
-6.31
-784.17%
-0.71
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
0.00
+100.00%
-10.61
-68.07%
-6.31
-784.17%
-0.71
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
0.00
+100.00%
-10.61
-68.07%
-6.31
-784.17%
-0.71
Net Long Term Debt Issuance
0.00
+100.00%
-10.61
-68.07%
-6.31
-784.17%
-0.71
Net Common Stock Issuance
-5.52
-178.61%
7.02
-69.58%
23.08
+112.61%
10.86
Common Stock Payments
-6.00
0.00
—
—
Repurchase Of Capital Stock
-6.00
0.00
—
—
Proceeds From Stock Option Exercised
20.57
-52.17%
43.00
+22.83%
35.01
0.00
Net Other Financing Charges
—
—
—
—
Changes In Cash
10.97
-44.43%
19.75
+2314.18%
0.82
+105.45%
-15.02
Effect Of Exchange Rate Changes
0.07
+312.50%
-0.03
-157.14%
0.06
+148.70%
-0.12
Beginning Cash Position
32.41
+155.29%
12.70
+7.39%
11.82
-56.14%
26.95
End Cash Position
43.45
+34.07%
32.41
+155.29%
12.70
+7.39%
11.82
Free Cash Flow
20.97
+208.99%
-19.24
+38.55%
-31.31
-24.44%
-25.16
Interest Paid Supplemental Data
0.00
-100.00%
1.24
-15.28%
1.46
-22.10%
1.87
Income Tax Paid Supplemental Data
1.54
0.00
—
—
Amortization Of Securities
-1.70
-188.93%
-0.59
-288.74%
-0.15
0.00
Common Stock Issuance
0.48
-93.15%
7.02
-69.58%
23.08
+112.61%
10.86
Interest Paid CFO
0.00
+100.00%
-0.85
0.00
—
Issuance Of Capital Stock
0.48
-93.15%
7.02
-69.58%
23.08
+112.61%
10.86
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category